These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease. Park H; Oh J; Shim G; Cho B; Chang Y; Kim S; Baek S; Kim H; Shin J; Choi H; Yoo J; Kim J; Jun W; Lee M; Lengner CJ; Oh YK; Kim J Nat Neurosci; 2019 Apr; 22(4):524-528. PubMed ID: 30858603 [TBL] [Abstract][Full Text] [Related]
8. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Crews L; Rockenstein E; Masliah E Brain Struct Funct; 2010 Mar; 214(2-3):111-26. PubMed ID: 20091183 [TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage. Sun J; Carlson-Stevermer J; Das U; Shen M; Delenclos M; Snead AM; Koo SY; Wang L; Qiao D; Loi J; Petersen AJ; Stockton M; Bhattacharyya A; Jones MV; Zhao X; McLean PJ; Sproul AA; Saha K; Roy S Nat Commun; 2019 Jan; 10(1):53. PubMed ID: 30604771 [TBL] [Abstract][Full Text] [Related]
10. Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders. De Plano LM; Calabrese G; Conoci S; Guglielmino SPP; Oddo S; Caccamo A Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955847 [TBL] [Abstract][Full Text] [Related]
11. Efficient SSA-mediated precise genome editing using CRISPR/Cas9. Li X; Bai Y; Cheng X; Kalds PGT; Sun B; Wu Y; Lv H; Xu K; Zhang Z FEBS J; 2018 Sep; 285(18):3362-3375. PubMed ID: 30085411 [TBL] [Abstract][Full Text] [Related]
13. Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice. Duan Y; Ye T; Qu Z; Chen Y; Miranda A; Zhou X; Lok KC; Chen Y; Fu AKY; Gradinaru V; Ip NY Nat Biomed Eng; 2022 Feb; 6(2):168-180. PubMed ID: 34312508 [TBL] [Abstract][Full Text] [Related]
14. Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer's Disease. Narayanan SE; Sekhar N; Rajamma RG; Marathakam A; Al Mamun A; Uddin MS; Mathew B Curr Protein Pept Sci; 2020; 21(12):1164-1173. PubMed ID: 32957903 [TBL] [Abstract][Full Text] [Related]
15. The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease. Rohn TT; Kim N; Isho NF; Mack JM J Alzheimers Dis Parkinsonism; 2018; 8(3):. PubMed ID: 30090689 [TBL] [Abstract][Full Text] [Related]
16. Application of CRISPR/Cas9 in Alzheimer's Disease. Lu L; Yu X; Cai Y; Sun M; Yang H Front Neurosci; 2021; 15():803894. PubMed ID: 34992519 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Genome Editing and In Vivo Delivery. Ramirez-Phillips AC; Liu D AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099 [TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 Ortiz-Virumbrales M; Moreno CL; Kruglikov I; Marazuela P; Sproul A; Jacob S; Zimmer M; Paull D; Zhang B; Schadt EE; Ehrlich ME; Tanzi RE; Arancio O; Noggle S; Gandy S Acta Neuropathol Commun; 2017 Oct; 5(1):77. PubMed ID: 29078805 [TBL] [Abstract][Full Text] [Related]
20. Activation of melatonin receptor 1 by CRISPR-Cas9 activator ameliorates cognitive deficits in an Alzheimer's disease mouse model. Park H; Kim J J Pineal Res; 2022 Apr; 72(3):e12787. PubMed ID: 35133672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]